Drug intelligence / Profile preview

ADSTEM

Development stage: Phase 3
Lead developer: EHL Bio
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ADSTEM is a biological drug developed by EHL Bio Co., Ltd. It is an injectable formulation of autologous mesenchymal stem cells, currently undergoing clinical trials for the treatment of moderate to severe subacute and chronic atopic dermatitis. The drug is administered intravenously to evaluate its safety and efficacy in patients with this dermatological condition.

Other names: ADSTEM Inj.

Beyond the preview

Go deeper on ADSTEM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADSTEM.

Explore the full profile